First City Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

First City Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-625	Closed	-$23.9K	–	404
2016 Q1	$23.9K	Hold	625	–	–	0.02%	366
2015 Q4	$31.6K	Hold	625	–	–	0.02%	336
2015 Q3	$28.6K	Buy	+625	New	+$34.9K	0.02%	346
2015 Q1	–	Sell	-625	Closed	-$31.4K	–	614
2014 Q4	$31.4K	Buy	+625	New	+$30.6K	0.02%	323
2014 Q3	–	Sell	-625	Closed	-$27.3K	–	641
2014 Q2	$27.3K	Hold	625	–	–	0.02%	343
2014 Q1	$26K	Buy	+625	New	+$26.7K	0.02%	345

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

First City Capital Management's PBE Position: Q2 2016 in Review

First City Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2016, closing a stake of 625 shares — an estimated $23.9K sold.

First City Capital Management first reported a position in PBE in Q1 2014 and held it in 6 quarters. The position peaked at $31.6K in Q4 2015. 73 funds tracked by Wall St. Rank hold PBE as of Q2 2016.

First City Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2016 after selling out during the quarter.
First City Capital Management sold 625 Invesco Biotechnology & Genome ETF shares in Q2 2016, an estimated $23.9K.
First City Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 6 quarters.
First City Capital Management's Invesco Biotechnology & Genome ETF position peaked at $31.6K in Q4 2015.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2016.

Based on First City Capital Management's 13F filing for Q2 2016, filed 16 Aug 2016.